University of Texas at Austin: Dry powder inhalation could be a potent tool in COVID-19 antiviral treatment

University of Texas at Austin: Dry powder inhalation could be a potent tool in COVID-19 antiviral treatment. “The only antiviral drug currently used to treat SARS-CoV-2, the coronavirus that causes COVID-19, is remdesivir, but administering it is invasive and challenging. Scientists at The University of Texas at Austin are hoping to change that by using their novel thin-film-freezing technology to deliver remdesivir through dry powder inhalation, potentially making treatment more potent, easier to administer and more broadly available.”

India coronavirus: Life-saving Covid-19 drugs sold on Delhi black market (BBC)

BBC: India coronavirus: Life-saving Covid-19 drugs sold on Delhi black market. “A BBC investigation has found that two life-saving drugs used to treat Covid-19 patients in India – remdesivir and tocilizumab – are in short supply and being sold for excessive rates on a thriving black market. Vikas Pandey reports from the capital Delhi.”

Coronavirus: US buys nearly all of Gilead’s Covid-19 drug remdesivir (BBC)

BBC: Coronavirus: US buys nearly all of Gilead’s Covid-19 drug remdesivir. “The US is buying nearly all the next three months’ projected production of Covid-19 treatment remdesivir from US manufacturer Gilead. The US health department announced on Tuesday it had agreed to buy 500,000 doses for use in American hospitals.”

Reuters: U.S. group raises pricing recommendation for Gilead’s remdesivir in COVID-19

Reuters: U.S. group raises pricing recommendation for Gilead’s remdesivir in COVID-19. “Gilead Sciences Inc’s (GILD.O) antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.”

CNN: The US government’s supply of Covid-19 drug remdesivir runs out at the end of the month

CNN: The US government’s supply of Covid-19 drug remdesivir runs out at the end of the month. “The US government’s current supply of remdesivir, the only drug known to work against Covid-19, will run out at the end of the month, Dr. Robert Kadlec, a US Department of Health and Human Services official, told CNN. The government’s last shipment of the drug will go out the week of June 29. Gilead Sciences, the company that makes the drug, is ramping up to make more, but it’s unclear how much will be available this summer.”

CNN: How does the government decide who gets remdesivir? Doctors have no idea

CNN: How does the government decide who gets remdesivir? Doctors have no idea. “It’s the first and only drug shown to be effective against the novel coronavirus in a rigorous trial. Its effects are modest but significant — shortening a patient’s hospital stay by about four days. Dr. Anthony Fauci, the nation’s top infectious disease specialist, has called it the new ‘standard of care’ for Covid-19. But as it stands now, there’s only enough remdesivir in the world for about 200,000 patients, according to the drug’s maker, Gilead Sciences. Who will those patients be? The US government, which is deciding where remdesivir goes, has offered few answers and little guidance since the drug was authorized for use on hospitalized patients a week ago.”

New York Times: Data on Gilead Drug Raises Hopes in Pandemic Fight, Fauci Calls It ‘Highly Significant’

New York Times: Data on Gilead Drug Raises Hopes in Pandemic Fight, Fauci Calls It ‘Highly Significant’. “The top U.S. infectious disease official said Gilead Sciences Inc’s experimental antiviral drug remdesivir will become the standard of care for COVID-19 after early results from a key clinical trial on Wednesday showed it helped patients recover more quickly from the illness caused by the coronavirus.”

Exclusive: Trial of Gilead’s potential coronavirus treatment running ahead of schedule, researcher says (Reuters)

Reuters: Exclusive: Trial of Gilead’s potential coronavirus treatment running ahead of schedule, researcher says. “Remdesivir has drawn tremendous attention as a therapy with the potential to alter the course of the disease, based on anecdotal reports that it may have helped some patients. Those hopes were dampened somewhat on Thursday, when details from a Chinese remdesivir trial in patients with severe COVID-19 inadvertently released by the World Health Organization suggested it provided no benefit. Gilead pushed back on that interpretation saying the study, which was stopped early due to low patient enrollment, cannot provide meaningful conclusions.”

STAT: New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope

STAT: New data on Gilead’s remdesivir, released by accident, show no benefit for coronavirus patients. Company still sees reason for hope . “The antiviral medicine remdesivir from Gilead Sciences failed to speed the improvement of patients with Covid-19 or prevent them from dying, according to results from a long-awaited clinical trial conducted in China. Gilead, however, said the data suggest a ‘potential benefit.’ A summary of the study results was inadvertently posted to the website of the World Health Organization and seen by STAT on Thursday, but then removed.”

National Institutes of Health: Antiviral remdesivir prevents disease progression in monkeys with COVID-19

National Institutes of Health: Antiviral remdesivir prevents disease progression in monkeys with COVID-19. “Early treatment with the experimental antiviral drug remdesivir significantly reduced clinical disease and damage to the lungs of rhesus macaques infected with SARS-CoV-2, the coronavirus that causes COVID-19, according to National Institutes of Health scientists.”